A5041185886- Advanced Breast Cancer Therapies
- AI in cancer detection
- Breast Cancer Treatment Studies
- Digital Radiography and Breast Imaging
- Global Cancer Incidence and Screening
- HER2/EGFR in Cancer Research
- Breast Lesions and Carcinomas
- Chemotherapy-induced cardiotoxicity and mitigation
- Cancer Treatment and Pharmacology
- Radiomics and Machine Learning in Medical Imaging
- Cancer-related Molecular Pathways
Praxis für Hämatologie und Onkologie
2025
Ravensburg University of Cooperative Education
2024
University Hospital Münster
2022-2024
University of Münster
2022-2024
PURPOSE The global, phase 3, open-label, randomized TROPION-Breast01 study assessed the trophoblast cell surface antigen 2–directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) versus investigator's choice of chemotherapy (ICC) in hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) breast cancer. METHODS Adult patients with inoperable/metastatic HR+/HER2‒ cancer, who had disease progression on endocrine therapy, for whom therapy was...
Background Digital breast tomosynthesis (DBT) plus synthesized mammography (SM) reduces the diagnostic pitfalls of tissue superimposition, which is a limitation digital (DM). Purpose To compare invasive cancer detection rate (iCDR) DBT SM versus DM screening for different density categories. Materials and Methods An exploratory subanalysis TOmosynthesis SYnthesized MAmmography (TOSYMA) study, randomized, controlled, multicenter, parallel-group trial recruited within German program from July...
Background Breast cancer screening with digital breast tomosynthesis (DBT) plus synthesized mammography (SM) increases invasive tumor detection compared (DM). However, it is not known how the prognostic characteristics of cancers detected two approaches differ. Purpose To compare DBT SM (test arm) versus DM (control regard to stage, histologic grade, patient age, and density. Materials Methods This exploratory subanalysis Tomosynthesis Synthesized Mammography (TOSYMA) study, which a...
Abstract Background: Ribociclib (RIB) + endocrine therapy (ET) showed statistically significant progression-free survival (PFS) and overall (OS) benefits in MONALEESA-2, -3, -7 patients (pts) with HR+/HER2− advanced breast cancer (ABC). Here, we report efficacy, safety, quality of life (QOL) RIB ET elderly pts the MONALEESA trials. Methods: Data were pooled from trials pre- postmenopausal ABC treated first-line or placebo (PBO) ET. The tamoxifen cohort MONALEESA-7 early relapse excluded this...
Abstract Screening with digital breast tomosynthesis plus synthetic mammography (DBT+SM) increases invasive cancer detection compared to (DM). Since a reduction in mortality is largely based on the of histological grade 2 or 3 cancers, comparison rates cancers (iCDR), independent stage, grades 3, was carried out, taking into account density, after screening DBT+SM vs. DM. The 1:1 randomized, multicenter TOSYMA study recruited participants from 7/2018 12/2020 German Mammography Program. This...